ArticleAmerican journal of hematology2023

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.

Meletios A Dimopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.